[Correspondence] Maintaining genomic surveillance using whole-genome sequencing of SARS-CoV-2 from rapid antigen test devices

Genomic sequencing of SARS-CoV-2 has had a major role in the public health response to the COVID-19 pandemic, enabling mapping of viral transmission at global and local levels, informing infection control measures, and, importantly, identifying and tracking the emergence of new SARS-CoV-2 variants.1–3 The rapid detection and characterisation of new variants is crucial for informing the potential efficacy of vaccines and therapeutics. With point-of-care rapid antigen tests replacing PCR as the main diagnostic modality in many settings, opportunities for genomic characterisation of circulating variants are increasingly limited.